Our Criteria for Target Selection

Ability to leverage our team’s expertise

Opportunity for portfolio synergy

Compelling biological validation

Target structure can be determined (structural enablement)

Potential for best-in-class drug candidate

The OnKure team is comprised of proven drug discovery and development scientists who are combining their cancer biology, medicinal chemistry and development expertise to create a robust pipeline of new candidates. Our leadership team made significant contributions to the success of Array BioPharma, a highly renowned small molecule drug discovery company, which was acquired by Pfizer in 2019. We are confident in our ability to repeat past successes, including the discovery of several marketed oncology drugs. Our drug discovery and development acumen positions us well to write the next chapter in oncology precision medicines.